- FDA approved RYBREVANT FASPRO™ for EGFR-mutated NSCLC on December 17, 2025.
- RYBREVANT FASPRO™ reduces administration time to five minutes and lowers side effects.
- Phase 3 PALOMA-3 study confirmed consistent results with RYBREVANT®.
- MARIPOSA study showed significant survival benefits with RYBREVANT® plus LAZCLUZE® combination.
FDA Approval
On December 17, 2025, the FDA approved RYBREVANT FASPRO™ for patients with EGFR-mutated non-small cell lung cancer (NSCLC). This marks the first subcutaneously administered therapy for this condition.
Benefits of RYBREVANT FASPRO™
Compared to intravenous delivery, RYBREVANT FASPRO™ significantly reduces administration time to five minutes and lowers the incidence of administration-related reactions and venous thromboembolism.
Clinical Study Results
The Phase 3 PALOMA-3 study demonstrated that RYBREVANT FASPRO™ delivers consistent results with RYBREVANT®, meeting key pharmacokinetic endpoints. The study also showed improved duration of response, progression-free survival, and overall survival compared to intravenous administration.
Combination Therapy
In the MARIPOSA study, the combination of RYBREVANT® and LAZCLUZE® showed a significant reduction in the risk of death compared to osimertinib. The combination therapy also demonstrated a lower incidence of acquired resistance mechanisms.
